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Abstract
Background: To determine: in vitro binding affinity of equol for 5alpha-dihydrotestosterone (5alpha-DHT), in vitro
effects of equol treatment in human prostate cancer (LNCap) cells, and in vivo effects of equol on rat prostate
weight and circulating levels of sex steroid hormones.
Methods: First, in vitro equol binding affinity for 5alpha-DHT was determined using 14C5alpha-DHT combined with
cold 5alpha-DHT (3.0 nM in all samples). These steroids were incubated with increasing concentrations of equol (0-
2,000 nM) and analyzed by Sephadex LH-20 column chromatography. 14C5alpha-DHT peak/profiles were
determined by scintillation counting of column fractions. Using the 14C5alpha-DHT peak (0 nM equol) as a
reference standard, a binding curve was generated by quantifying shifts in the 14C5alpha-DHT peaks as equol
concentrations increased. Second, equol’s in vitro effects on LNCap cells were determined by culturing cells (48
hours) in the presence of increasing concentrations of dimethyl sulfoxide (DMSO) (vehicle-control), 5alpha-DHT,
equol or 5alpha-DHT+equol. Following culture, prostate specific antigen (PSA) levels were quantified via ELISA.
Finally, the in vivo effects of equol were tested in sixteen male Long-Evans rats fed a low isoflavone diet. From 190-
215 days, animals received 0.1cc s.c. injections of either DMSO-control vehicle (n = 8) or 1.0 mg/kg (body weight)
of equol (in DMSO) (n = 8). At 215 days, body and prostate weights were recorded, trunk blood was collected and
serum assayed for luteinizing hormone (LH), 5alpha-DHT, testosterone and 17beta-estradiol levels.
Results: Maximum and half maximal equol binding to 5alpha-DHT occurred at approximately 100 nM and 4.8 nM
respectively. LNCap cells cultured in the presence of 5alpha-DHT significantly increased PSA levels. However, in the
presence of 5alpha-DHT+equol, equol blocked the significant increases in PSA levels from LNCap cells. In vivo
equol treatment significantly decreased rat prostate weights and serum 5alpha-DHT levels but did not alter LH,
testosterone, and estradiol levels.
Conclusions: Equol administration appears to have potential beneficial effects for prostate health and other
5alpha-DHT mediated disorders. Equol administration: reduces PSA levels from LNCap cells under 5alpha-DHT
stimulation, decreases rat prostate size, decreases serum 5alpha-DHT levels and androgen hormone action, while
not altering other circulating sex steroids or LH levels.
Background
Polyphenols are a group of chemical substances found
in plants that include berries, grapes, walnuts, peanuts,
pomegranates, and other fruits and vegetables [1]. Many
of these polyphenol preparations are available as dietary
supplements [2]. The largest and best studied polyphe-
nols are the dietary estrogen-like molecules or phytoes-
trogens [1]. Of the three main classifications of
phytoestrogens: 1) isoflavones (derived principally from
soybeans), 2) lignans (found in flaxseed in large quanti-
ties), and 3) coumestans (derived from sprouting plants
like alfalfa), human consumption of isoflavones has the
largest impact due to its availability and variety in food
products. Isoflavones have been implicated as potential
treatments for many disorders including cardiovascular
disease, osteoporosis, age-related diseases, and hor-
mone-dependent cancers [3,4].
However, these isoflavone molecules do not exist at
high levels in their biologically active form in natural
food products, but rather are at high abundance in a
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sor of daidzein, is the glycosidic form that contains a
carbohydrate portion of the molecule. Daidzin is meta-
bolized in the gastrointestinal tract by intestinal bacteria,
which hydrolyze the carbohydrate moiety, to the biologi-
cally active isoflavone, daidzein [4,5]. Daidzein is then
further metabolized in the intestine to equol at relatively
low or high levels dependent upon several biological,
dietary and presumably environmental factors [4,5].
Although, recent evidence suggests that equol is found
naturally in white cabbage [6].
Equol has recently caught the interest of many research-
ers due to its rich antioxidant activity and implications in
cancer research [4,5]. The chemical structure of equol
contains a stereocenter at carbon number 3 which gives it
two possible enantiomers and it has since been proven
that the production of equol by microflora in mammals or
other animals is selective for the S - enantiomer only [5].
S-equol has unique chemical properties compared to its
R - enantiomer. S-equol has been shown to have a modest
affinity for binding to and mimicking estrogen’s effects on
estrogen beta receptors (ERb) due to its similar structure
to natural estrogens [5,7]. However, S-equol shows little
affinity for estrogen alpha receptors (ERa). Furthermore,
equol (i.e., the R- and/or S-isomer) can act as an anti-
androgen [7]. Equol’s anti-androgen activity is unique as
equol does not bind the androgen receptor (AR) but speci-
fically binds 5a-dihydrotestosterone (5a-DHT) with high
affinity, and thereby prevents DHT from binding the AR
[7], see Figure 1. This finding is reconfirmed and extended
here. Additionally, equol’s mechanism of action, namely,
its ability to specifically bind 5a-DHT and prevent 5a-
DHT’s biological actions in physiological processes, was
studied.
For example, it is known that prostate cancer cells are
supported in their growth by androgen stimulation and
the androgen-regulated expression of the prostate speci-
fic antigen (PSA) is a biological marker of such stimula-
tion [8]. Logically, any treatment that could decrease PSA
levels in prostate cancer cells, or antagonize specific
androgen hormone action, would have great potential in
addressing prostate disorders, such as benign prostatic
hyperplasia (BPH) or prostate cancer. With this in mind,
w es o u g h t ,i nt h ef o l l o w i n ge x p e r i m e n t s ,t od e t e r m i n e
equol’s effect on 5a-DHT levels in cultured human pros-
tate cancer (LNCap) cells. We also examined equol’s
effect on both prostate weight and circulating hormone
levels in vivo using Long-Evans rats. In brief, the present
results demonstrate that equol: a) (R- and/or S-isomeric
mixtures) has high binding affinity for 5a-DHT making it
a potent selective androgen modulator (SAM), b) blocks
the stimulatory androgen action of 5a-DHT in increasing
prostate specific antigen (PSA) levels in human cancer
(LNCap) cell cultures and, c) significantly decreases
serum 5a-DHT and subsequently prostate weight with-
out altering, testosterone, 17b-estradiol or LH levels.
Applications for equol to improve prostate disorders and
other androgen-mediated conditions is also discussed.
Methods
Experiment 1. In vitro binding of Equol (Isomer Ratio) to
5a-DHT
Samples
In a 20 ml amber glass vial approximately 4,000 to 5,000
dpm of
14C5a- Dihydrotestosterone (DHT; Dupont/
NEN, Boston, MA, USA) was added. Additionally, 3.0
nM (or approximately 865 pg/ml) of cold 5a-DHT
(Sigma/Aldrich Chemical Co., St. Louis, MO, USA) was
added (in all experiments) and where appropriate vary-
ing concentrations of equol (70% R-equol and 30% S-
equol mixture; from 0 to 2,000 nM; obtained from LC
Labs., Woburn, MA,USA or Robert Handa’s Laboratory,
Colorado State University, USA, R-equol or S-equol iso-
mers only) from ethanol stock solutions. This mixture
was vortexed for 30 seconds at room temperature and
then dried down. Subsequently 1 ml of TEGMD (10
mM Tris CL, 1.5 mM EDTA, 10% glycerol, 25 mM
molybdate and 1 mM dithrothreitol) buffer was added,
capped, and mixed by inverting the vial 3-times. This
mixture was incubated at room temperature for 20-24
hours before being placed on a Sephadex column [7].
Columns
Sephadex LH-20 (25-100 μm particle diameter) from
Sigma/Aldrich Chemical Co. (St. Louis, MO, USA), was
used to prepare 1.3 cm × 25 cm columns, as described
by Lund et al [7]. Sephadex (0.25 grams) was mixed
with 1.5 ml of TEGMD buffer. The serological pipette
was plugged with a glass bead and 1 ml of Sephadex
was loaded onto the column with TEGMD buffer and
equilibrated. Flow rates under gravity were approxi-
mately 0.5 ml/min and 0.5 ml fractions were collected
in plastic scintillation vials.
Quantification
Five ml of Ultima Gold scintillation fluid (Packard Instr.
Co., Meriden, CT, USA) was added to each vial, mixed
Figure 1 Biochemical structures of dihydrotestosterone and
equol.
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6500 scintillation counter. The peak
14C5a-DHT frac-
tion and profile using 0 nM of equol was used as refer-
ence. The shift (advancement) in peak/profile in
subsequent experiments using increasing concentrations
of equol (70% R-isomer and 30% S-isomer in this
experiment) was calculated based upon this reference
(as arbitrary binding units as a percentage of the original
reference, n = 6 for 0 nM of equol). Note: data not
shown, 2,000 nM of equol was tested in this experiment
which yielded 100.0% ± 0.3 (s.e.m.) binding, n = 3.
Finally, over thirty steroid hormones were tested (see
Table 1) (in preliminary studies to determine the selec-
tivity and specificity of equol for binding 5a-DHT). The
steroids were purchased from Steraloids, Inc., Newport,
RI, USA or Sigma/Aldrich Chem. Co., St. Louis, MO,
USA.
Experiment 2. In vitro blockade of 5a-DHT stimulated
Prostate Specific Antigen (PSA) levels in LNCap cells by
equol: Human Prostate Cancer Cell Cultures
Human prostate cancer cell line was obtained from
American Type Culture Collection (ATCC; Manassas,
VA, USA; ATCC # CRL-1740, LNCap-FGC) and cul-
tured in a 37° C, humidified incubator with 5% CO2,i n
RPMI Medium (Sigma/Aldrich Cat. # R-8758) with 5%
fetal bovine serum (Hyclone/Thermo Sci., Waltham,
MA, USA, Cat. # SH30088.03, Lot number APC20780)
and 5 mM Hepes (Sigma/Aldrich Cat. H-0887), 1× anti-
biotic/antimycotic (Sigma/Aldrich Cat. # A5955). Cells
were expanded in T-150 flasks for three passages until
cryopreservation and storage in liquid nitrogen in RPMI
medium with 10% FBS and 10% DMSO as cryopreserva-
tive. A cryovial was then thawed in a 37° C water bath,
expanded again one or two passages, and then plated at
Table 1 Steroid compounds tested in Equol Binding Assays
Chemical Name Trivial Name
4-ANDROSTEN-17b-OL-3-ONE TESTOSTERONE
5-ANDROSTEN-3b-OL-17-ONE DHEA
5a-ANDROSTAN-3a,17b-DIOL 17b-DIHYDROANDROSTERONE
5a-ANDROSTAN-3b,17a-DIOL NA
5a-ANDROSTAN-3b,17b-DIOL NA
5a-ANDROSTAN-3,17-DIONE ANDROSTANEDIONE
5a-ANDROSTAN-17b-OL-3-ONE 5a-DHT
5b-ANDROSTAN-17b-OL NA
5b-ANDROSTAN-17b-OL-3-ONE 5b-DHT
4-ANDROSTEN-3,17-DIONE ANDROSTENEDIONE
1,3,5(10)-ESTRATRIEN-3,17a-DIOL EPIESTRADIOL
1,3,5(10)-ESTRATRIEN-3,17b-DIOL ESTRADIOL (E2)
1,3,5(10)-ESTRATRIEN-3,16a,17b-TRIOL ESTRIOL (E3)
1,3,5(10)-ESTRATRIEN-3-OL-17-ONE ESTRONE (E1)
5a-ESTRAN-3,17-DIONE 5a-DIHYDROANDROSTENEDIONE
5-PREGNEN-3b-OL-20-ONE PREGNENOLONE
4-PREGENEN-3,20-DIONE PROGESTERONE (P4)
5a-PREGNAN-3a-OL-20-ONE ALLOPREGNANOLONE
5a-PREGNAN-11b,21-DIOL-3, 20-DIONE ALLODIHYDROCOSTERONE
5a-PREGNAN-3a,11b,21-TRIOL-20-ONE ALLOTETRAHYDROCORTICOSTERONE
5a-PREGNAN-3b,2 1 b, 21-TRIOL-20-ONE EPIALLOTETRAHYDROCORTICOSTERONE
5a-PREGNAN-3b,11b,17,21-TETROL-20-ONE 3b,5 a-TETRAHYDROCORTISOL
5a-PREGNAN-11b,17,21-TRIOL-3,20-DIONE ALLODIHYDROCORTISOL
5a-PREGNAN-17,21-DIOL-3,11,20-TRIONE ALLODIHYDROCORTISONE
5a-PREGNAN-3b-OL-20-ONE 5a-DIHYDROPREGNANOLONE
5a-PREGNAN-3, 20-DIONE 5a-DIHYDROPROGESTERONE (5a-DHP)
5b-PREGNAN-3a-OL-20-ONE 3a-HYDROXY-5bTETRAHYDROPROGESTONE
5b-PREGNAN-11b,21-DIOL-3,20-DIONE 5b -DIHYDROCORTICOSTERONE
5b-PREGNAN-3a,11b,21-TRIOL-20-ONE TETRAHYDROCORTICOSTERONE
5b-PREGNAN-3a,11b,17,21-TETROL-20-ONE TETRAHYDROHYDROCORTISOL
5b-PREGNAN-11b,17,21-TRIOL-3,20-DIONE 5b-DIHYDROCORTISOL
5b-PREGNAN-17,21-DIOL-3,11,20-TRIONE 5b -DIHYDROCORTISONE
5b-PREGNAN-3,20-DIONE 5b-DIHYDROPROGESTERONE (5b-DHP)
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plates in RPMI 5% FBS medium. After approximately
48 hours, the medium was changed to phenol red-free
DMEM/F12 (Gibco/Invitrogen, Carlsbad, CA, USA, Cat.
#21041-025) with 2% FBS and 1× antibiotic/antimycotic
and test materials (5a-DHT, equol or 5a-DHT plus
equol; n = 6 per treatment) and DMSO/vehicle controls
were added at the appropriate concentration (either, 0.1
nM, 1.0 nM or 10 nM of 5a-DHT or 100 nM, 10 nM
or 1.0 nM of equol) from 10× stocks for specific experi-
ments. [The change to phenol red-free medium was to
eliminate any potential estrogenic influence]. Cells were
cultured for approximately 48 hours in the presence of
the test materials and controls prior to removal of med-
ium supernatants for prostate specific antigen (PSA)
ELISA quantification.
MTT Assay
Cytotoxicity was determined by spectrophotometric
detection of reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma/Aldrich
Cat # 5655) at 550 nm using a Molecular Devices Vmax
96 well plate reader and SoftMax software (n = 6 per
treatments or controls). Metabolic activity can be used
as a measure of cytotoxicity, in that the intensity of the
reduced form of MTT by live cells is directly propor-
tional to cellular viability, and inversely proportional to
cytotoxicity.
Cellular DNA Assay
Cellular DNA was determined using a CyQuant Cell
Proliferation Kit (Molecular Probes/Invitrogen, Carlsbad,
CA, USA, Cat # C7026) according to the manufacture’s
instructions to quantify cellular proliferation.
PSA ELISA
Tissue culture supernatants were diluted 10-fold in PBS
and stored at -20°C, then thawed at room temperature
prior to assay. A commercial ELISA kit for free PSA
( B i o - Q u a n t ,S a nD i e g o ,C A ,U S A ,C a t .#B Q0 6 7 T )w a s
utilized according to the manufacturer’s instructions,
and data was determined using a Molecular Devices
Vmax 96 well plate reader and SoftMax software.
Experiment 3. In vivo blockade of the stimulatory effects
of 5a-DHT by equol
This is an example of equol preventing the stimulatory
effects of 5a-DHT in vivo. Rats were injected with 1 mg
of non-racemic equol (52% S-isomer, 48% R-isomer) for
25 consecutive days, and serum 5a-DHT levels and
prostate weights were measured. Adult (50 day-old)
males (n = 16), purchased from Charles River Labora-
tories (CRL; Wilmington, MA, USA), were caged indivi-
dually and housed in the Brigham Young University
Vivarium and maintained on an 11-dark, 13-hour light
schedule (lights on 0600-1900). Before purchase, the
male animals were fed a diet containing approximately
200 ppm of isoflavones at the supplier (CRL). At 50
days of age, upon arrival, the male rats were placed on a
diet containing approximately 10 ppm of isoflavones;
referred to hereafter as the low isoflavone diet (Zeigler
Bros., Gardnes, PA, USA; Phytoestrogen Reduced
Rodent Diet II). All animals remained on the low isofla-
vone diet until 216 days of age to exclude the influence
of dietary isoflavones on the measured parameters. At
150 days of age the rats were divided into two groups
(control or equol treatments) that were matched by age
and body weight. Starting at 190 days of age the male
rats received a daily subcutaneous 0.1cc injection at the
nape of the neck of vehicle (n = 8) (dimethyl sulfoxide;
DMSO) or equol (n = 8) at a dose of approximately 1.0
mg/kg for 25 consecutive days.
The body weights for each group were recorded
weekly starting at 150 days of age before the treatments
were initiated, with weights obtained immediately before
and after the treatments were administered (there were
no significant differences in body weights between the
control and equol groups at the start of this experi-
ment). At 216 days of age the animals were weighed
[grams (g) ± 0.1 g], then anesthestized with Ketamine/
acepromazine and blood was collected from the heart.
Next the ventral prostate organ was dissected and
weighed [milligrams (mg) ± 0.001 mg]. The collected
blood samples were centrifuged and serum was stored
at -20˚ C until assayed. All collection procedures were
performed blind to the treatments. This animal protocol
was approved by the Institutional Animal Care and Use
Committee at Brigham Young University.
Serum testosterone, 5a-DHT, and 17b-estradiol were
quantified by radioimmunoassay (RIA) kits purchased
from Diagnostic System Laboratories (Webster, TX, USA).
Luteininzing hormone (LH) was quantified by an assay
utilizing standards from the National Institutes of Health
(NIH) USA pituitary hormone program. The samples
were run in duplicate for each RIA, with internal control
samples. In all RIAs, the control values were within nor-
mal ranges. The intra-assay coefficients of variance for the
assays were: testosterone = 6.0%; for 5a-dihydrotestoster-
one = 8%, 17b-estradiol = 5% and LH = 9%.
Reagents and supplies
All reagents and supplies not specifically mentioned
(e.g., EDTA, DMSO, glycerol, dithrothreitol, pipettes, 1.3
× 25 cm columns, etc.) were purchased from Sigma/
Aldrich Chem. Co., St. Louis, MO, USA.
Statistical analyses
W h e r ea p p r o p r i a t e ,d a t aw e r ea n a l y z e db ya n a l y s i so f
variance statistics (ANOVA) followed by Newman-Keuls
post hoc tests. Significance was p < 0.05. Curve fitting,
scientific graphing, and analysis were completed using
GraphPad Software (GraphPad Prism 3.0, San Diego,
CA, USA).
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Experiment 1
In preliminary studies, Table 1 shows 33 different ster-
oid compounds that were tested in binding assays (out-
lined above) to determine equol’s affinity for binding to
each. While equol has modest affinity for some 5a-
reduced steroids, equol displayed the highest affinity for
5a-dihydrotestosterone (5a-DHT) and had no affinity
for 5b-dihydrotestosterone (5b-DHT) or some of the
most common natural sex steroids, such as: estradiol,
estrone, estriol, progesterone or testosterone. [Notably:
as tested in these assays, the isoflavones: genistein and
daidzein do not bind 5a-DHT].
As shown in Figure 2, using
14C5a-DHT as the tracer
in the presence of 3.0 nM (or approximately 865 pg/ml)
of cold DHT (in all samples, representing a high-normal
level of circulating 5a-DHT in men) varying concentra-
tions of equol (70% R-equol and 30% S-equol mixture)
from 0 to 2,000 nM yielded the binding curve displayed
in this Figure. [The 2,000 nM dose is not graphically
displayed in this Figure]. Maximum and half maximal
equol binding to 5a-DHT occurred at approximately
100 nM and 4.8 nM, respectively. The number of sam-
ples tested at each concentration of equol examined
ranged between 2 to 6 replicates (see Figure 2). [For
conversion purposes, a concentration of 10.3 nmol/L of
equol is approximately equivalent to 2.5 ng/ml of equol].
Notably, equol at a 70% R-isomer and 30% S-isomer
ratio was tested in this experiment. However, racemic
equol or equol at a 30% R-isomer and 70% S-isomer
ratio when tested in these assays yielded similar results
to that displayed in Figure 2. These data suggest that
equol, regardless of the isomer ratio mixture can bind-
ing selectively 5a-DHT in vitro.
Experiment 2
This is an example of the effects of equol preventing the
stimulatory effects of 5a-DHT in LNCap prostate cancer
cells in vitro from secreting prostate-specific antigen
(PSA), a molecule known to be regulated by 5a-DHT,
as measured by PSA ELISA (Figure 3). Treatment with
0 . 1 ,1o r1 0n Mo f5 a-DHT; 1, 10 or 100 nM of equol
or a combination of 5a-DHT plus equol (0.1 nM 5a-
DHT and 1 nM equol; 1 nM 5a-DHT and 10 nM equol
or 10 nM 5a-DHT and 100 nM equol). Each obtained
value represents 6 replicates + standard error of the
mean (sem). Cytotoxicity, as assessed by MTT Assay,
did not influence PSA production by LNCap prostate
cancer cells for any of the treatments or controls (data
not shown). Also, while DHT treatment has been
reported to increase cellular proliferation of this cell line
in vitro [9], none of the treatments significantly altered
cellular proliferation as quantified by the cellular DNA
assay (data not shown).
As shown in Figure 3: In the 1, 10 or 100 nM Vehicle
(DMSO) treatments PSA levels did not differ from the
No Treatment baseline group and controls were not sig-
nificantly different from each other. Treatment with 0.1,
1o r1 0n M5 a-DHT stimulated PSA secretion to
Figure 2 In vitro binding of equol (isomer ratio) to 5a-DHT.
14C5a- Dihydrotestosterone served as the tracer and 3.0 nM (or
approximately 865 pg/ml) of cold 5a-DHT was added (in all
experiments) and where appropriate varying concentrations of
equol (70% R-equol and 30% S-equol mixture; from 0 to 2,000 (see
methods). All data expressed as the mean of the percent binding ±
SEM (see insert).
Figure 3 In vitro evidence: The effects of 5a-DHT or equol
alone and in combination on prostate specific antigen (PSA)
by LNCap Human Prostate Cancer Cells. All data expressed as the
mean + the standard error of the mean (sem). Up black triangle
significantly greater levels in all 5a-DHT treatments compared to all
other treatments (p < 0.0001) Down black triangle, significant
decrease at 100 nM of equol vs. all control values (p < 0.0001). Black
square, slight but significant increase in PSA levels in the equol 10
nM group compared to DMSO-vehicle values (p < 0.008) but not to
the no-treatment group (p < 0.47). Three horizontal lines, significant
decrease at 10 nm of 5a-DHT plus equol at 100 nM compared to
10 nM of 5a-DHT alone (p < 0.0001). Two horizontal lines,
significant decrease at 1 nM of 5a-DHT plus equol at 10 nM
compared to 1 nM of 5a-DHT alone (p < 0.001). One horizontal
line, represent a significant decrease at 0.1 nM of 5a-DHT plus
equol at 1 nM compared to 0.1 nM of 5a-DHT alone (p < 0.042).
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levels from cells treated with 1, 10 or 100 nM equol
were well below DHT-treated values. In fact, the 100
nM equol treatment alone yielded a PSA level at 60 ng/
ml that was significantly decreased below all vehicle-
control values (at approximately 87 ng/ml). The equol
treatment at 10 nM slightly but significantly increased
PSA levels (to 116.7 ng/ml) compared to all the DMSO-
vehicle-control values around 87 ng/ml, but not to the
no-treatment group at 100 ng/ml). [This may be due to
the number of replicates (6) in this experiment where
standard error of the mean (sem) values were relatively
small]. However, combinations of 10 nM 5a-DHT plus
100 nM equol, as well as 1 nM 5a-DHT plus 10 nM
equol, and 0.1 nM 5a-DHT plus 1 nM equol treatments
abrogated the increase in PSA secretion, compared to
the 5a-DHT treatments alone, at the respective andro-
g e nc o n c e n t r a t i o n s( s e eF i g u r e3 ) .T a k e nt o g e t h e rw i t h
the in vitro binding demonstrated in Figure 2, these
data from experiment 2, suggest that equol binds the
5a-DHT molecule and biologically inactivates it in
human cancer prostate cells.
Experiment 3
To determine whether equol can bind 5a-DHT in vivo,
adult male Long-Evans rats were treated with equol for
25 consecutive days (@ 1 mg/kg via s.c. injections).
Equol-injected animals displayed an approximately 50%
decrease in serum 5a-DHT compared to (DMSO) vehi-
cle-injected control animals (Table 2). This finding cor-
responds with the significant decrease in androgen
hormone action which is known to regulate prostatic
cell proliferation, and hence, prostate weight. Prostate
weights were significantly decreased by approximately
20% in the equol-injected males compared to control
rats (either alone or when prostate weights were stan-
dardized with body weights).
When LH and testosterone were quantified between the
treatment groups there were no significant differences in
these hormone levels (Table 2). Since LH is the gonado-
trophin regulating testosterone synthesis from Leydig cells
in the testes, this is not a surprising result. Finally, when
17b-estradiol levels were determined there were no signifi-
cant differences between the treatment groups. All hor-
mone levels were within normal ranges of that expected
for this strain, age and sex of rat. Notably, Long-Evans rats
do not develop spontaneously prostate cancer but enlarge-
ment of prostatic tissue is observed with aging.
This in vivo study demonstrates that equol can con-
tact and biologically inactive the 5a-DHT molecule as
shown by the significant decrease in 5a-DHT levels in
blood and significantly reduced prostate weights of
equol-treated male rats. Finally, the in vitro and in vivo
studies reported above demonstrates that equol may be
effective in treating prostate disorders or other andro-
gen-mediated diseases that are regulated by the hor-
mone 5a-DHT.
Discussion
The binding assays in the present study confirm and
extend previous findings from our laboratories [7]. How-
ever, this protein and cell-free assay represents a system
that is absent of steroid-binding proteins and other biolo-
gicals that may influence the in vivo interaction between
equol and 5a-DHT. Moreover, after testing over 30 ster-
oid hormones with various androgenic, estrogenic or pro-
gestin chemical configurations, equol (racemic or non-
racemic mixtures) specifically binds 5a-DHT with appar-
ent equal affinity since the bind curves obtained were
very similar using different equol isomer ratios. This sug-
gests several important issue s .F i r s t ,a l lh u m a n sh a v e
plasma levels of S-equol circulating in their bloodstream
that may represent a natural modulation of the potent
androgen, 5a-DHT, regardless of whether or not they are
“equol producers” [4,5]. Second, this circulating equol is
derived from consumption of soy- or high content isofla-
vone-containing food products or low abundant isofla-
v o n ef o o d ss u c ha sc o r n ,w h e a t ,c o w ’s milk, etc., as a
primary consumer. Finally, because grazing or other ani-
mals that produce high levels of S-equol naturally that
are then consumed, such as meat products, by humans
represents a source of equol as a secondary consumer.
Evidence to support this last notion is shown in humans
that consume high meat and fat diets display higher
blood isoflavone/equol levels [10].
This denotes an interesting ‘natural’ modulation of
5a-DHT in humans, since all individuals consume food
products that contain the precursor daidzein molecule
or equol itself (i.e., soy, corn, wheat, cow’s milk or ani-
mal meat products, etc.) [4,6,11-13]. In fact, whether or
not swine were fed a soy-containing or protein-supple-
mented diet the serum equol levels between the dietary
treatment groups were essential the same [14]. Since the
apparent half-maximal binding of equol to 5a-DHT
occurred at 4.8 nM (or approximately 1.2 ng/ml) the
Table 2 Serum 5a-DHT levels, prostate weights and
reproductive parameters in Equol-treated male rats
Parameter measured Vehicle Equol Change
Prostate Weight (PW), mg 535 ± 23 429 ± 30** 20%↓
PW/100 g Body Weight 76 ± 4 61 ± 5** 20%↓
Luteinizing Hormone (LH), ng/ml 1.6 ± 0.2 1.3 ± 0.1 NSC
Serum Testosterone, ng/ml 2.1 ± 0.4 2.3 ± 0.5 NSC
Serum 5a-DHT, pg/ml 100 ± 18 52 ± 5* 50%↓
Serum 17b-Estradiol, pg/ml 3.4 ± 0.6 4.8 ± 0.7 NSC
n = 8 animals per group. NSC = no significant change. The data are expressed
as the mean ± standard error of the mean (sem) for each parameter.
** = p < 0.016 * = p < 0.001.
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hormone action in a manner previous unknown in nor-
mal physiological conditions. Also, the apparent half-life
of R- or S-equol in humans is 5 to 6 hours [5], suggest-
ing a viable time interval and mechanism of action.
While the present data were derived from in vitro bind-
ing studies that does not represent the complex physio-
logical environment this viewpoint will be covered
below in reference to prostate health.
Further evidence presented in this study for equol bind-
ing 5a-DHT is presented in the experiment where equol
blocked the stimulatory androgen action of 5a-DHT in
increasing PSA levels in human cancer cell cultures.
Although, this may be the major mechanism of action, it
is known that equol (particularly S-equol) has an affinity
for ERb [5]. Previous laboratories, including ours, have
shown that isoflavones binding to ERb in the prostate can
down regulate the androgen receptor (AR) and thus
decrease androgen hormone action [15]. Since PSA is an
androgen-regulated gene this idea may have merit [16,17].
In addition to equol directly binding 5a-DHT, it may alter
AR expression and hence significantly decreased PSA
levels in the present study. Support for this view comes
from the significant decrease in PSA levels with equol
treatment alone (@ 100 nM) in experiment 2 that dis-
played values even below baseline (vehicle) PSA concen-
trations. However, it could be argued that the fetal bovine
serum provided a background androgenic stimulation and
this may also account for this observation. In any event,
the results of this experiment demonstrate the positive
influence equol has on PSA levels and implicates potential
applications of equol for prostate disorders. Finally, phase
II clinical trial data examining dietary intervention with
isoflavone supplementation in men with recurrent prostate
cancer display a decline in PSA levels that support our
present in vitro data [18].
As mentioned earlier, equol has the ability to bind ERb.
This may explain how isoflavones accumulate in prostate
tissue and prostatic fluid after oral supplementation
[19-21] and it has been shown that binding ERb in the
prostate decreases inflammation and carcinogenesis [22].
Furthermore, this not only applies to prostate health but
to other tissue-specific sites in the body where ERb is
present. For example, there is an abundance of ERb in
the brain, specifically in the frontal cortex and raphe
nuclei as well as other brain regions that may be involved
in mechanisms of anxiety and depression [23-25]. Preli-
minary data from our laboratory suggest that equol treat-
ment in aged-rats after natural ovarian failure is effective
as an anti-depressive agent at low concentrations that
significantly increase serotonin levels. Additionally, the
skin represents the largest organ of the body where ERb
is abundant in the epidermal and dermal regions, espe-
cially the keratinocytes and fibroblasts, respectively
which may be tissue sites for beneficial alterations in
androgen hormone action [26]. For instance, it is known
the androgens decrease, whereas, estrogenic compounds
enhance wound healing [27] that may have effective
applications for topical treatments.
The results of the third experiment demonstrated that
equol can significantly decrease serum 5a-DHT along
with a significant decline in prostate weight without
altering, testosterone, 17b-estradiol or LH levels. There
is evidence that Asian cultures have lower prostate can-
cer rates compared to Western cultures [1,3,28].
Furthermore, when data is stratified examining indivi-
duals that produce equol naturally after soy consump-
tion suggest that lower cancer rates are due to the
beneficial influence of this isoflavonoid molecule [29].
Moreover, while equol has been shown to have posi-
tive benefits in human prostate health, there is evidence
that R-, rather than the S - enantiomer is responsible
for the in vivo chemoprotective properties of equol [30].
Additionally, from pilot data, serum 5a-DHT levels
significantly decreased by 10 to 15% in men (50 to 60
years of age) and 20 to 26% in postmenopausal women
(60 to 65 years of age) when an equol oral dose of 3 mg
per day was administered (without side effects), suggest-
ing that equol effectively binds and/or alters 5a-DHT
levels. This pilot data is supported by a recent study
showing isoflavone supplementation that increased the
production of serum equol in equol-producers resulted
in a decline in serum 5a-DHT levels in men by approxi-
mately 18% versus before supplementation values [31].
Conclusions
In summary, our in vitro studies reveal equol binds spe-
cifically 5a-DHT and prevents increases in PSA from
LNCap cells, while the in vivo studies demonstrate that
equol decreases rat prostate size, decreases serum 5a-
DHT levels and androgen hormone action, while not
altering other circulating sex steroids or LH levels.
Taken together these data suggest a potential use of
equol as a therapeutic agent for men’s prostate health.
For example, benign prostate hyperplasia (BPH or pros-
tate enlargement) that is manifested by nocturia (need
to urinate frequently during the sleep-cycle), frequency
of urination during the day or night, decreased voided
urine volume, sensory urgency to urinate, inability to
start and stop a urine stream, etc., where equol may
mediate androgen hormone action of 5a-DHT and/or
androgen steroid receptor inactivation is influenced by
binding ERb in a positive manner.
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